48L Stock Chart & Stats
€65.60
--
Market closed
€65.60
--
Day’s Range― - ―
52-Week Range€65.60 - €65.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€2.65M
Enterprise Value€15.66
Total Cash (Recent Filing)€15.22M
Total Debt (Recent Filing)€23.60M
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Nov 16, 2026EPS Estimate
-2.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-53.60
Shares Outstanding984,407
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)18.70
Price to Sales (P/S)14.92
P/FCF Ratio-5.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.71Price Target Upside-86.72% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.53
Revenue Forecast (FY)€10.92M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling And Growth OutlookThe company has moved from negligible revenue to a commercial base of approximately $7.7 million, demonstrating initial customer adoption of LungFit. Management’s reiterated 2026 and 2027 targets provide a visible growth framework, although delivery depends on broader adoption and Gen II commercialization.
Expanded Hospital Access And DistributionAdding a third national group purchasing organization can broaden access across U.S. hospitals and reduce barriers to procurement. Distribution in more than 40 countries also expands the addressable commercial footprint, creating more channels for device placements and recurring consumable utilization.
Improving Unit Economics And Capital AllocationSequential quarters of positive gross profit and a four-point year-over-year margin improvement indicate that LungFit economics are moving in the right direction from a very low base. Lower R&D spending also reflects tighter allocation toward commercialization, potentially extending resources for market expansion.
Bears Say
Severe Profitability DeficitThe current revenue base is not yet sufficient to cover the company’s cost structure, with very low gross margin and exceptionally large losses relative to sales. Until margins improve materially and operating expenses scale more efficiently, growth may continue requiring substantial capital rather than producing self-funded earnings.
Persistent Cash Burn And Funding DependenceOngoing negative operating and free cash flow limits financial flexibility and makes execution dependent on access to additional capital. Although the burn rate has improved versus prior years, continued cash usage can pressure strategic choices and increase the risk of financing-related shareholder dilution.
Gen II Approval And Launch Timing RiskThe ambitious 2027 revenue outlook includes potential Gen II launch revenue, so regulatory timing is a material dependency for the growth plan. Delayed approval would postpone commercialization, defer expected adoption and leave the company reliant on the slower growth of its existing LungFit offering.
Beyond Air News
48L FAQ
What was Beyond Air Inc’s price range in the past 12 months?
Beyond Air Inc lowest stock price was €65.60 and its highest was €65.60 in the past 12 months.
What is Beyond Air Inc’s market cap?
Beyond Air Inc’s market cap is €2.65M.
When is Beyond Air Inc’s upcoming earnings report date?
Beyond Air Inc’s upcoming earnings report date is Nov 16, 2026 which is in 56 days.
How were Beyond Air Inc’s earnings last quarter?
Beyond Air Inc released its earnings results on Aug 13, 2026. The company reported -€9.501 earnings per share for the quarter, missing the consensus estimate of -€9.329 by -€0.173.
Is Beyond Air Inc overvalued?
According to Wall Street analysts Beyond Air Inc’s price is currently Overvalued.
Does Beyond Air Inc pay dividends?
Beyond Air Inc does not currently pay dividends.
What is Beyond Air Inc’s EPS estimate?
Beyond Air Inc’s EPS estimate is -2.86.
How many shares outstanding does Beyond Air Inc have?
Beyond Air Inc has 984,407 shares outstanding.
What happened to Beyond Air Inc’s price movement after its last earnings report?
Beyond Air Inc reported an EPS of -€9.501 in its last earnings report, missing expectations of -€9.329. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Beyond Air Inc?
Currently, no hedge funds are holding shares in DE:48L
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyond Air Inc
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
48L Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a constructive, growth-oriented outlook: management strengthened the balance sheet via a financing, secured important commercial partnerships (including a third national GPO), expanded international distribution, and showed improving unit economics (gross margin up to 13%) while reducing R&D spend. The company reaffirmed 2026 guidance and provided an ambitious multi‑year revenue target for 2027 tied to the potential Gen II LungFit PH launch. Key risks highlighted include flat current revenue, ongoing net losses and cash burn, increased other expense, and regulatory timing uncertainty for Gen II approval. On balance, the positives around financing, commercial traction, margin improvement, and a doubled pipeline outweigh the near-term operational and regulatory risks.View all DE:48L earnings summaries48L Stock 12 Month Forecast
Average Price Target
€8.71
▼(-86.72% Downside)